Search

everythinglearnresearchcommunity

for

Search:↓

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

Melatonin may help with sleep issues, depression, and cancer, but more research is needed.

Spironolactone is a safe and effective treatment for reducing excessive hair growth in women.

GABRA2 gene variations impact alcohol response, and hair loss medication finasteride reduces some effects.

Human hair follicle organ culture is a useful model for hair research with potential for studying hair biology and testing treatments.

Stress can cause hair loss by negatively affecting hair follicles and this effect might be reversed with specific treatments.

Polycystic Ovary Syndrome likely starts in childhood and may be genetic and influenced by early hormone exposure.

In late pregnancy, allopregnanolone reduces stress responses in rats by affecting brain chemicals.

Hair follicles produce and respond to melatonin, affecting hair growth and sensitivity to estrogen.

The telogen phase of hair growth is active and important for preparing hair follicles for regeneration, not just a resting stage.

Hair grows faster in the morning and is more vulnerable to damage from radiation due to the internal clock in hair follicle cells.

Melatonin helps regulate hair growth and protects the hair follicle from stress.

Manipulating the catagen and telogen phases of hair growth could lead to treatments for hair disorders.

The conclusion is that early diagnosis and a multi-system treatment approach are crucial for managing PCOS and its associated health risks.

TRH stimulates human hair growth and extends the hair growth phase.

Human hair follicles produce and respond to erythropoietin, helping protect against stress.

PCOS affects women's health by increasing the risk of diabetes, heart disease, and reproductive issues.

The current methods for diagnosing polycystic ovary syndrome are too vague and may lead to misdiagnosis and problems in research.

LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.

Excessive hair growth in women often has no known cause and is not linked to race or other hormonal symptoms.

Testosterone replacement may improve sexual desire and bone health in women with low androgen levels, but more research is needed on its long-term safety.

Metformin and rosiglitazone both improved insulin use and hormonal symptoms in women with PCOS.

Melatonin solution helps treat hair loss in men and women.

Adrenal disorders can cause lasting brain and behavior issues in children.

DHT's role in hair loss is important, but measuring its level for diagnosis is questionable.

Behçet's Disease may be caused by genetic and environmental factors leading to abnormal immune responses, and stress management and new treatments could improve patient outcomes.

Women with hyperandrogenic amenorrhea have similar bone density to healthy women but lower than androgenized women without amenorrhea, and high DHEAS levels might affect bone density.

Obese and non-obese women with PCOS have higher heart risk markers, especially if they are obese.

Early diagnosis and treatment of PCOS is crucial to reduce emotional distress and health risks.

Testosterone therapy can help improve mood, sexual function, and bone health in women with low androgen levels, but more research is needed to establish safe and effective guidelines.